

Figure 2




Figure 3




Figure 4

INCIONED IIINI

Chiral .

Figure 5

SB-328636

| | | | - | | | | | | | \neg | |
|-------|---------------|--------------------|-------------|------------|-------------|------------------|---------------------|---------------|------------------|------------------|-------------------|
| PAL-2 | 0.54 | | ug/mil.) | φ & | 0.5 | < 0.06 | >64 | 0.25 | > 0.06 | > 0.06 | |
| PAL-1 | ТВО | | MICs (ng/mr | >64 | 40 | >04 0.05 | 2.0 | t c | 7 7 | 2 0 | |
| | RLB IC50 (uM) | S30 TMet 1030 (mm) | Crasnism | E coli DC0 | E. coli DC2 | H. influenzae Q1 | M. catarrhalis 1502 | E. faecalis I | S. aureus Oxford | S. pneumoniae R6 | S. pyogenes CN 10 |

Figure 6.





Figure 7.






Figure 9.



D 3H PAL-1

+ unlabelec plauromutilin




Figure 10.



+ unlabeled pieuromutilin

□ 3H PAL-2





Figure 11.

Ribosomal Proteins










Figure 13.

4








Fig 15




Figure 16..




Figure 17.




Figure 18.




Figure 19.

| | | | | _ | _, | _ | | _ | _ | _ | _ | _ | _ | _ | _ | - | _ | 7 | _ | _ | Т | | _ | _ | ٦ |
|---------------------------------------|-----------|---------------|-------------|---------------|---------------|-------------|-------------|-------------|-------------|--------------|-------------|---------|-----------|------|--------------|-------------|------|--------|-------|--------------------|--------------------|-------------------|--------------------|-------------------|-------------------|
| S30 Coupled Transcription/Transla ion | ICSO (um) | 0.5 +/- 0.1 | 1.4 +1-0.2 | 0.45 +/- 0.08 | 0.58 +/- 0.09 | 1.5 +/- 0.2 | 2.3 +/- 0.4 | 1.8 +/- 0.2 | 0.4 +/- 0.1 | 0.7 +/- 0.08 | 18+-0.3 | 1947.02 | 100 | 1864 | 1,1±0.2 | 2.6 +/- 0.3 | >250 | 31+1-4 | | | 0.79 | | | , | 0.99 |
| S30 [3H] fmet IC50 (uM) | | 0.25±0.03 | 0 18+0 02 | 0 4040 03 | 0.5+0.1 | 1 4+0 5 | 0.28+0.05 | 4 640 08 | David Co. | 2007.007 | 207 | 1.4±0.7 | 0.47±.08 | ы | 50% at 50 uM | 12±0.2 | >250 | 6±2 | | | 66.0 | | | | 0.98 |
| Radioligand Binding (RLB) | IC50 (nM) | 0 67 1/- 0 04 | 000 14 16.0 | 0.99 +/- 0.09 | 0.43 +/- 0.09 | 0.7 +1-0. | 00 / 67 | 1.0-1-0.5 | 1.8 +/- 0.4 | 2.7 +/- 0.4 | 1.1 +/- 0.5 | 8#1 | 0.8+/-0.3 | 12±3 | 18±4 | 2.5 +/- 0.3 | >250 | 0476 | 625.5 | | 96 | 0.00 | | | * |
| S. aureus Oxford MICs | (ng/mf-) | 90.0 | on:00≥ | × 0.06 | 0.125 | 0.125 | 4 | 2 | 2 | 2 | 2 | 4 | 4 | ×84 | | , | | 2 | 35 | | _ | × | | | |
| SB Compound | | | V | 7 | ¥ | _ | × | z | ш | 4 | O | 0 | - | - | E | - - | 0 | | S | Correlation versus | MICs (R value from | linear regression | Correlation versus | RLB (R value from | linear regression |

Fia 20.

PCT/US00/12133




Figure 21.





Figure 22.

WO 00/71560

 $\mathbf{\omega}$



| ı | | | | |
|----------|---|-------|--------------|-----------|
| <u> </u> |] | 20 | | |
| Ļ٥ | . 4 | 18 20 | | |
| Ľ۷ | 1 | 91 | | |
| Ł | 4 | 4 | (S | |
| E | 1 | 2 | Time (Hours) | |
| F | L I | 10 12 | 9 | |
| F | 1 - | - | Ē | |
| F | 1 7 | | | |
| F | 1 7 | 9 | | |
| \vdash | \ | 4 | | က |
| F | | 7 | | 2 |
| L | July Continue of the Continue | 0 | | Ĭ |
| 2.2 | 2 1.8 1.6 1.7 1.2 1.2 0.8 0.6 | | | Figure 23 |
| | bauod basgiloibsz mą | | | - |
| | | | | |

77